HC Wainwright reiterated their buy rating on shares of ASLAN Pharmaceuticals (NASDAQ:ASLN – Free Report) in a report released on Monday morning, Benzinga reports. They currently have a $9.00 target price on the stock.
Separately, Piper Sandler reissued an overweight rating and issued a $10.00 target price (down from $15.00) on shares of ASLAN Pharmaceuticals in a research note on Wednesday, March 13th.
View Our Latest Research Report on ASLN
ASLAN Pharmaceuticals Stock Performance
Institutional Investors Weigh In On ASLAN Pharmaceuticals
Several hedge funds and other institutional investors have recently made changes to their positions in ASLN. UBS Group AG acquired a new stake in shares of ASLAN Pharmaceuticals in the 4th quarter valued at $326,000. Renaissance Technologies LLC boosted its position in shares of ASLAN Pharmaceuticals by 574.1% in the 2nd quarter. Renaissance Technologies LLC now owns 475,896 shares of the company’s stock worth $236,000 after purchasing an additional 405,296 shares during the last quarter. Citigroup Inc. bought a new position in shares of ASLAN Pharmaceuticals in the 4th quarter worth $104,000. Virtu Financial LLC boosted its position in shares of ASLAN Pharmaceuticals by 389.6% in the 4th quarter. Virtu Financial LLC now owns 88,106 shares of the company’s stock worth $32,000 after purchasing an additional 70,109 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in shares of ASLAN Pharmaceuticals by 34.4% in the 1st quarter. Bank of America Corp DE now owns 259,722 shares of the company’s stock worth $233,000 after purchasing an additional 66,544 shares during the last quarter. 58.82% of the stock is owned by institutional investors and hedge funds.
ASLAN Pharmaceuticals Company Profile
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.
See Also
- Five stocks we like better than ASLAN Pharmaceuticals
- What is Short Interest? How to Use It
- The Charles Schwab Company Can Hit New Highs
- What is a SEC Filing?
- Costco vs. Walmart: Revenue Comparison of Two Retail Giants
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
Receive News & Ratings for ASLAN Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.